Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Loans - Loss Allowance: 2019-2022

Historic Loans - Loss Allowance for Autolus Therapeutics (AUTL) over the last 4 years, with Dec 2022 value amounting to $173.1 billion.

  • Autolus Therapeutics' Loans - Loss Allowance rose 167.78% to $125.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $125.9 million, marking a year-over-year increase of 167.78%. This contributed to the annual value of $173.1 billion for FY2022, which is 90.38% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Loans - Loss Allowance of $173.1 billion as of FY2022, which was up 90.38% from $90.9 billion recorded in FY2021.
  • Over the past 5 years, Autolus Therapeutics' Loans - Loss Allowance peaked at $173.1 billion during FY2022, and registered a low of $88.9 billion during FY2019.
  • Over the past 3 years, Autolus Therapeutics' median Loans - Loss Allowance value was $90.9 billion (recorded in 2021), while the average stood at $117.6 billion.
  • Data for Autolus Therapeutics' Loans - Loss Allowance shows a peak YoY skyrocketed of 90.38% (in 2022) over the last 5 years.
  • Over the past 4 years, Autolus Therapeutics' Loans - Loss Allowance (Yearly) stood at $88.9 billion in 2019, then remained steady at $88.9 billion in 2020, then increased by 2.27% to $90.9 billion in 2021, then skyrocketed by 90.38% to $173.1 billion in 2022.